Safety Study of BAY73-4506 in Patients With Hepatocellular Carcinoma
The purpose of this study is to determine whether BAY73-4506 treatment is safe and can shrink or delay the growth of tumors in patients with unresectable liver cancer.
Carcinoma, Hepatocellular
DRUG: BAY73-4506
Adverse Event Collection, Up to 30+/- 7 days after permanently discontinuing BAY73-4506 administration
Time to progression, Every 6 weeks during treatment and after 6 cycle treatment every 18 weeks till progression|Objective response rate, Every 6 weeks during treatmen and after 6 cycle treatment every 18 weeks till progression|Disease control rate, Every 6 weeks during treatmen and after 6 cycle treatment every 18 weeks till progression|Overall survival, Every 6 weeks during treatmen and after 6 cycle treatment every 18 weeks till progression|Trough concentration of Regorafenib and metabolites (for Europe only), Cycle 1 Day 15 and Cycle 2 Day 1|Full Pharmacokinetics profile of BAY73-4506 and metabolites (for Korea only), Cycle 1 Day 21 to Day 28
The purpose of this study is to determine whether BAY73-4506 treatment is safe and can shrink or delay the growth of tumors in patients with unresectable liver cancer.